Narcolepsy: Current treatment options and future approaches

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 3, 2008, Pages 557-566

  Billiard, Michel ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Conventional drugs; Future treatments; Modafinil; Narcolepsy; Sodium oxybate; Treatment

Indexed keywords

4 CHLOROMETHAMPHETAMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE; IMIPRAMINE; IMMUNOGLOBULIN; MAZINDOL; METHYLPHENIDATE; MODAFINIL; NORADRENALIN; OREXIN; OXYBATE SODIUM; PEMOLINE; PHENELZINE; PLACEBO; PROTIRELIN; PROTRIPTYLINE; REBOXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VESICULAR MONOAMINE TRANSPORTER 2; VILOXAZINE;

ADRENERGIC ACTIVITY; ANOREXIA; ANTICHOLINERGIC EFFECT; ASTHMA; BEDTIME DOSAGE; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CATAPLEXY; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIZZINESS; DRUG BINDING SITE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EJACULATION DISORDER; ENURESIS; ENZYME INHIBITION; ERECTILE DYSFUNCTION; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPNAGOGIC HALLUCINATION; HYPOTENSION; IMMUNOTHERAPY; IMPOTENCE; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LIVER TOXICITY; LOW DRUG DOSE; MORNING DOSAGE; NARCOLEPSY; NAUSEA; NERVOUSNESS; NONHUMAN; OROFACIAL DYSKINESIA; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; RHINITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SWEATING; TACHYCARDIA; TREATMENT PLANNING; URINARY DYSFUNCTION; VALVULAR HEART DISEASE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 47849091141     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Akimoto H, Honda Y, Takahashi Y. 1960. Pharmacotherapy in narcolepsy. Dis Nerv Syst, 21:1-3.
2. American Academy of Sleep Medicine. 2005. International classification of sleep disorders, 2nd ed.:Diagnostic and coding manual. Westchester, Illinois: American Academy of Sleep Medicine.
3. Arias-Carrion O, Murillo-Rodriguez E, Xu M, et al. 2004. Transplantation of hypocretin neurons into the pontine reticular formation:preliminary results. Sleep, 27:1465-70.
4. Arias-Carrion O, Drucker-Colin R, Murillo-Rodriguez E. 2006. Survival rates through time of hypocretin grafted neurons within their projection site. Neurosci lett, 404:93-7.
5. Beer B, Stark J, Krieter P, et al. 2004. DOV 216,303, a 'triple' reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol, 44:1360-7.
6. Beuersterien KM, Rogers AAE, Walsleben JA, et al. 1999. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep, 22:757-65.
7. Billiard M, Bassetti C, Dauvilliers Y, et al. 2006. EFNS guidelines on management of narcolepsy. Eur J Neurol, 13:1035-48.
8. Billiard M, Besset A, Montplaisir J, et al. 1994. Modafinil: a double-blind multicenter study. Sleep, 17(Suppl):107-12.
9. Billiard M, Nicolet A, Dauvilliers Y, et al. 2007. Modafinil: the European experience. In Bassetti C, Billiard M, Mignot E. (eds) Narcolepsy and hypersomnia. New York. Informa Healthcare, pp. 561-9.
10. Black J, Houghton WC. 2006. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep, 2:939-46.
11. Boeve BF, Silber MH, Ferman TJ. 2003. Melatonin for treatment of REM sleep behavior disorder in neurological disorders:results in 14 patients. Sleep Med, 4:281-A.
12. Britton T, Hansen A, Hicks J, et al. 2002. Guidelines on the diagnosis and management of narcolepsy in adults and children. Evidence-based guidelines for the UK with graded recommendations. Ashtead, UK: Taylor Patten Communications Ltd.
13. Broughton R, Ghanem Q, Hishikawa Y, et al. 1981. Life effects of narcolepsy in 180 patients from North-America, Asia and Europe compared to matched controls. Can J Neurol Sci, 8:299-304.
14. Broughton RJ, Fleming JAE, George CFP, et al. 1997. Randomized, double-blind placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology, 49:444-51.
15. Broughton R, Mamelak M. 1979. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci, 6:1-6.
16. Broughton RJ, Murray BJ. 2007. The behavioral management of narcolepsy. In Bassetti C, Billiard M, Mignot E. (eds) Narcolepsy and hypersomnia. New York. Informa Healthcare, p 497-512.
17. Chemelli RM, Willie JT, Sinton CM, et al. 1999. Narcolepsy in orexin knockout mice:molecular genetics of sleep regulation. Cell, 98:437-51.
18. Chen W, Black J, Einen M, et al. 2005. Late onset narcolepsy presenting as rapidly progressing muscle weaknes:response to plasmaphoresis. Ann Neurol, 58:489-90.
19. Chokroverty S. 1986. Sleep apnea in narcolepsy. Sleep, 9:250-3.
20. Dauvilliers Y, Carlander B, Touchon J, et al. 2004. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol, 56:905-8.
21. Dauvilliers Y, Montplaisir J, Molinari N, et al. 2001. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology, 57:2029-33.
22. Fronczek R, Overeem S, Lammers GJ, et al. 2006. Altered skin-temperature regulation in narcolepsy relates to sleep propensity. Sleep, 29:1444-49.
23. Fronczek R, Raymann RJEM, Romeijn N, et al. 2008. Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. Sleep, 31:233-40.
24. Fronczek R, Verschuuren J, Lammers GJ. 2007. Response to intravenous immnoglobulin and placebo in a patient with narcolepsy with cataplexy. J Neurol, 254:1607-8.
25. Guilleminault C. 1993. Amphetamines and narcolepsy:use of the Stanford database. Sleep, 16:199-201.
26. Guilleminault C, Mancuso J, Quera-Salva MA, et al. 1986. Viloxazine hydrochloride in narcolepsy:a preliminary report. Sleep, 9:275-79,
27. Hanson LR, Martinez PM, Taheri S, et al. 2004. Intranasal administration of hypocretin-1 (orexin A) bypasses the blood-brain barrier and targets the brain:a new strategy for the treatment of narcolepsy. Drug Delivery Technol, 4:66-71.
28. Harsh JR, Hayduk R, Rosenberg R, et al. 2006. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin, 22:761-74.
29. Hecht M, Lin L, Kushida CA, et al. 2003. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep, 26:809-10.
30. Hublin C, Kaprio J, Partinen M, et al. 1994a. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol, 35:709-16.
31. Hublin C, Partinen M, Heinonen E, et al. 1994b. Selegiline in the treatment of narcolepsy. Neurology, 44:2095-101.
32. Iijima S, Sugita Y, Tshima Y, et al. 1986.Therapeutic effects of mazindol on narcolepsy. Sleep, 9:265-8.
33. Ivanenko A, Tauman R, Gauzal D. 2003. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med, 4:579-82.
34. Kales A, Vela-Bueno A, Kales JD. 1987. Sleep disorders:sleep apnea and narcolepsy. Ann Intern Med, 106:434-43.
35. Keam S, Walker MC. 2007. Therapies for narcolepsy with or without cataplexy:evidence based review. Curr Opin Neurol, 20:699-703.
36. Kent JM. 2000. SnaRIs, NaSSAs, and NARIs:new agents for the treatment of depression. Lancet, 355:911-18. Erratum in: Lancet, 355:2000.
37. Langdon N, Shindler J, Parkes JD, et al. Fluoxetine in the treatment of cataplexy. Sleep, 9:371-3.
38. Larrosa O, de la Llave Y, Bario S, et al. 2001. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy. Sleep, 24:282-5.
39. Lecendreux M, Maret S, Bassetti C, et al. 2003. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res, 12:347-8.
40. Lin L, Faraco J, Li R, et al. 1999. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 98:365-76.
41. Lin JS. 2000. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev, 4:471-503.
42. Lin JS, Sakai K, Vanni-Mercier G et al. 1990, Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res, 523:325-30.
43. Maitre M. 1997. The gamma-hydroxybutyrate signalling system in brain organisation and functional implications. Prog Neurobiol, 51:337-61.
44. Marelli S, Fantini M, Busek P, et al. 2006. Association between REM sleep behavior disorder and narcolepsy with and without cataplexy. Sleep, 29(Abstract Suppl):A229-30.
45. Martinez-Rodriguez J, Iranzo A, Santamaria J, et al. 2002. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia, 17:113-6.
46. Mayer G, Meier-Ewert K. 1995. Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol, 18:306-19.
47. Mayer G, Peter H, Kesper K, et al. 2002. Komorbidität bei Narkolepsiepatienten. Dtsch Med Wochenschr, 127:1942-46.
48. Merrit SL, Cohen FL, Smith KM. 1992. Depressive symptomatology in narcolepsy. In Goswami M, et al. (eds). Psychosocial Aspects of Narcolepsy. New York: The Haworth Press, p 53-9.
49. Mieda M, Willie JT, Hara J, et al. 2004. Orexin peptides prevent cataplexy and improve wakefulness in an orexin-neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA, 101:4649-54.
50. Mignot E, Nishino S, Guilleminault C, et al. 1994. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep, 17:436-7.
51. Mitler MM, Aldrich MS, Koob GF, et al. 1994. Narcolepsy and its treatment with stimulants (ASDA standards of practice). Sleep, 17:352-71.
52. Mitler MM, Shafor R, Hajdukovik R, et al. 1986. Treatment of narcolepsy: objective studies on methylphenidate, pemoline,and protriptyline. Sleep, 9:260-4.
53. Moldofsky H, Broughton RJ, Hill JD. 2000. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med, 1:109-16.
54. Montplaisir J, Michaud M, Denesle R, et al. 2000. Periodic leg movements are not more prevalent in insomnia or hypersomnia but are specifically associated with sleep disorders involving a dopaminergic impairment. Sleep Med, 1:163-7.
55. Morgenthaler TI, Kapur VK, Brown T, et al. 2007. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep, 30:1705-11.
56. Murali H, Kotagal S. 2006. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep, 29:1025-9.
57. Niederhofer H. 2005. Atomoxetine also effective in patients suffering from narcolepsy? Sleep, 28:1189.
58. Nightingale S, Orgill JC, Ebrahim IO, et al. 2005. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med, 6:253-8.
59. Nishino S, Arrigoni J, Shelton J, et al. 1997. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci, 17:6401-8.
60. Nishino S, Kanbayashi T. 2005. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/ orexin system. Sleep Med Rev, 9:269-310.
61. Nishino S, Mao J, Sampathkumaran R, et al. 1998. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online, 1:49-61.
62. Nishino S, Mignot E. 1997. Pharmacological aspects of human and canine narcolepsy. Progr Neurobiol, 52:27-78.
63. Ohayon MM, Priest RG, Zulley J, et al. 2002. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology, 58:1826-33.
64. Pardi D, Black J. 2006. GHB/sodium oxybate:neurobiology and impact on sleep and wakefulness. CNS Drugs, 20:993-1018.
65. Parkes JD, Dahlitz M. 1993. Amphetamine prescription. Sleep, 16:201-3.
66. Peyron C, Faraco J, Rogers W, et al. 2000. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med, 6:991-7.
67. Plazzi G, Montagna P, Provini F, et al. 2007. Treatment of narcolepsy with cataplexy. Lancet, 369:1081.
68. Prinzmetal M, Bloomberg W. 1935. The use of benzedrine for treatment of narcolepsy. JAMA, 105:2051-4.
69. Riehl J, Honda K, Kwan M, et al. 2000. Chronic oral administration of CG-3703, a thyrotropin-releasing hormone analog, increase wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology, 23:34-45.
70. Rogers AE, Aldrich MS, Lin X. 2001. Comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep, 24:385-91.
71. Roselaar SE, Langdon N, Lock CB, et al. 1987. Selegiline in the treatment of narcolepsy. Sleep, 10:491-5.
72. Schachter M, Parkes JD. 1980. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatr, 43:171-4.
73. Schenck CH, Mahowald MW. 1992. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol, 32:3-10.
74. Schwartz JR, Nelson MT, Schwartz ER, et al. 2004. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol, 27:74-9.
75. Shiba T, Fujiki N, Wisor J, et al. 2004. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep, 27(Abstract Suppl):A241-2.
76. Shindler J, Schachter M, Brincat S, et al. 1985. Amphetamines, mazindol and fencamfamin in narcolepsy. BMJ, 290:1167-70.
77. Silber MH, Black JL, Krahn LE, et al. 2007. Autoimmune studies in narcolepsy. In Bassetti C, Billiard M, Mignot E. (eds) Narcolepsy and hypersomnia. New York: Informa Healthcare. p 451-7.
78. Silber MH, Krahn LE, Olson EJ, et al. 2002. The epidemiology of narcolepsy in Olmsted county, Minnesota:a population-based study. Sleep, 25:197-202.
79. Smith M, Parkes JD, Dahlitz M. 1996. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res, 5(Suppl 1):217.
80. Standards of Practice Committee. 2001. Practice parameters for the treatment of narcolepsy:an update for 2000. Sleep, 24:451-66.
81. Standards of Practice Committee of the American Sleep Disorders Association. 1994. Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep, 17:348-51.
82. Tatsumi M, Groshan K, Blakely RD, et al. 1997. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol, 340:249-58.
83. Tedford CE, Edgar DM, Seidel WF, et al. 1999. Effects of a novel, selective and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy. Abstr Soc Neurosci, 25:1134.
84. Thannickal TC, Moore RY, Nienhuis R, et al. 2000. Reduced number of hypocretin neurons in human narcolepsy. Neuron, 27:469-74.
85. The Xyrem® International Study Group. 2005. A double-blind, placebo-controlled study demonstrates that sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med, 1:391-7.
86. Thorpy MJ, Black J, Erman MK. 2004. The safety profile of modafinil in disorders of sleep and wakefulness. Neurology, 62(Suppl 5): A56-7.
87. Thorpy MJ, Snyder M, Aloes ES, et al. Short-term triazolam use improves nocturnal sleep of narcolepstics. Sleep, 1992:15:212-6.
88. US Modafinil in Narcolepsy Multicenter Study Group. 1998. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol, 43:88-97.
89. US Modafinil in Narcolepsy Multicenter Study Group. 2000. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology, 54:1166-75.
90. US Xyrem® Multicenter Study Group. 2002. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep, 25:42-9.
91. US Xyrem® Multicenter Study Group. 2003. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep, 26:31-5.
92. US Xyrem® Multicenter Study Group. 2004. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med, 5:119-23.
93. Xyrem® International Study Group. 2005. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy:a double-blind, placebo-controlled study in 228 patients. Sleep Med, 6:415-21.
94. Wing YK, Li RH, Lam CW, et al. 2002. The prevalence of narcolepsy among Chinese in Hong-Kong. Ann Neurol, 51:578-84.
95. Wisor JP, Nishino S, Sora I, et al. 2001. Dopaminergic role in stimulant induced wakefulness. J Neurosci, 21:1787-94.
96. Wyatt RJ, Fram DH, Buchbinder R, et al. 1971. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med, 285:987-91
97. Zuberi SM, Mignot E, Ling L, et al. 2004. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res, 13(Suppl 1):828.